Transcenta 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
blosozumab (LY2541546) / Eli Lilly
NCT05391776: TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density

Recruiting
1
32
RoW
TST002 Injection, TST002-IgG4, placebo
HJB (Hangzhou) Co., Ltd.
Osteoporosis
04/23
06/23
betifisolimab (MSB2311) / Transcenta
MSB2311-CSP-002 , NCT04272944: A Study of MSB2311 in Advanced Solid Tumors

Completed
1
42
RoW
10 mg/kg Q2W, MSB2311 10 Q2W, 20 mg/kg Q3W, MSB2311 20 Q3W
Suzhou Transcenta Therapeutics Co., Ltd.
Advanced Solid Tumor
01/22
01/22
ozekibart (INBRX-109) / Inhibrx Biosci
2021-002635-35: A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarcoma). Estudio de fase 2, de INBRX-109 en adultos en un tipo de cancer de huesos y articulaciones irresecable o metastasico (condrosarcoma convencional)

Not yet recruiting
2
201
Europe
Desametasone, Difenidramina, INBRX-109, INBRX-109, Lyophilisate for solution for infusion
Inhibrx, Inc., Inhibrx, INC, Inhibrx, Inc.
Unresectable or metastatic conventional chondrosarcoma condrosarcoma convencional irresecable o metastásico., Malignant bone tumor that cannot be resected or it has been spread from the primary site (place where it started) to other places in the body. Tumor óseo maligno que no puede ser resecado o que se ha extendido desde el sitio primario (lugar donde comenzó) a otros lugares del cuerpo., Diseases [C] - Cancer [C04]
 
 
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
osemitamab (TST001) / Transcenta
NCT06093425: Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Not yet recruiting
3
950
NA
TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), TST001 and Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), folinic acid and oxaliplatin and Nivolumab, Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), Placebo and Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), folinic acid and oxaliplatin
Suzhou Transcenta Therapeutics Co., Ltd.
Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer
10/25
01/26
NCT05190575: TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

Completed
2
8
RoW
TST001
Shanghai Zhongshan Hospital, Transcenta Holding Limited
Biliary Tract Neoplasms
05/23
05/23
ChiCTR2100054990: An open-label, single-arm phase II clinical study evaluating the efficacy and safety of TST001 in the treatment of unresectable advanced or metastatic CLDN18.2-positive cholangiocarcinoma

Completed
2
40
 
Drug: TST001
Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University, Suzhou Transcenta Therapeutics Co., Ltd.
Biliary Tract Neoplasms
 
 
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
320
RoW
TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer
02/25
05/25
NCT05608785: Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Not yet recruiting
1/2
45
NA
IBI315, Oxaliplatin, Capecitabine, TST001, TQB2450, Anrotinib
Henan Cancer Hospital
Gastric Cancer, Gastroesophageal-junction Cancer
12/23
10/24
TransStar101, NCT04396821: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
150
US
TST001, Nivolumab Injection [Opdivo], mFOLFOX6, Gemcitabine, Gemzar, Albumin-Bound Paclitaxel
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
05/25
09/25
MSB0254 / Transcenta
NCT04381325: A Study of MSB0254 Injection in Advanced Solid Tumors

Terminated
1
25
RoW
MSB0254 Injection
Suzhou Transcenta Therapeutics Co., Ltd.
Advanced Solid Tumor
06/22
06/22
TST005 / Transcenta
NCT04958434: Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Terminated
1
19
US
TST005
Suzhou Transcenta Therapeutics Co., Ltd.
Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm
09/23
09/23
TST003 / Transcenta
NCT05731271: A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Active, not recruiting
1/2
111
US
TST003
Suzhou Transcenta Therapeutics Co., Ltd.
Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
05/25
08/25
TST010 / Transcenta
No trials found
TST004 / Transcenta
No trials found
TST008 / Transcenta
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
blosozumab (LY2541546) / Eli Lilly
NCT05391776: TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density

Recruiting
1
32
RoW
TST002 Injection, TST002-IgG4, placebo
HJB (Hangzhou) Co., Ltd.
Osteoporosis
04/23
06/23
betifisolimab (MSB2311) / Transcenta
MSB2311-CSP-002 , NCT04272944: A Study of MSB2311 in Advanced Solid Tumors

Completed
1
42
RoW
10 mg/kg Q2W, MSB2311 10 Q2W, 20 mg/kg Q3W, MSB2311 20 Q3W
Suzhou Transcenta Therapeutics Co., Ltd.
Advanced Solid Tumor
01/22
01/22
ozekibart (INBRX-109) / Inhibrx Biosci
2021-002635-35: A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarcoma). Estudio de fase 2, de INBRX-109 en adultos en un tipo de cancer de huesos y articulaciones irresecable o metastasico (condrosarcoma convencional)

Not yet recruiting
2
201
Europe
Desametasone, Difenidramina, INBRX-109, INBRX-109, Lyophilisate for solution for infusion
Inhibrx, Inc., Inhibrx, INC, Inhibrx, Inc.
Unresectable or metastatic conventional chondrosarcoma condrosarcoma convencional irresecable o metastásico., Malignant bone tumor that cannot be resected or it has been spread from the primary site (place where it started) to other places in the body. Tumor óseo maligno que no puede ser resecado o que se ha extendido desde el sitio primario (lugar donde comenzó) a otros lugares del cuerpo., Diseases [C] - Cancer [C04]
 
 
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
osemitamab (TST001) / Transcenta
NCT06093425: Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Not yet recruiting
3
950
NA
TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), TST001 and Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), folinic acid and oxaliplatin and Nivolumab, Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), Placebo and Oxaliplatin and capecitabine or 5-fluorouracil (5-FU), folinic acid and oxaliplatin
Suzhou Transcenta Therapeutics Co., Ltd.
Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer
10/25
01/26
NCT05190575: TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

Completed
2
8
RoW
TST001
Shanghai Zhongshan Hospital, Transcenta Holding Limited
Biliary Tract Neoplasms
05/23
05/23
ChiCTR2100054990: An open-label, single-arm phase II clinical study evaluating the efficacy and safety of TST001 in the treatment of unresectable advanced or metastatic CLDN18.2-positive cholangiocarcinoma

Completed
2
40
 
Drug: TST001
Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University, Suzhou Transcenta Therapeutics Co., Ltd.
Biliary Tract Neoplasms
 
 
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
320
RoW
TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer
02/25
05/25
NCT05608785: Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Not yet recruiting
1/2
45
NA
IBI315, Oxaliplatin, Capecitabine, TST001, TQB2450, Anrotinib
Henan Cancer Hospital
Gastric Cancer, Gastroesophageal-junction Cancer
12/23
10/24
TransStar101, NCT04396821: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
150
US
TST001, Nivolumab Injection [Opdivo], mFOLFOX6, Gemcitabine, Gemzar, Albumin-Bound Paclitaxel
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
05/25
09/25
MSB0254 / Transcenta
NCT04381325: A Study of MSB0254 Injection in Advanced Solid Tumors

Terminated
1
25
RoW
MSB0254 Injection
Suzhou Transcenta Therapeutics Co., Ltd.
Advanced Solid Tumor
06/22
06/22
TST005 / Transcenta
NCT04958434: Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Terminated
1
19
US
TST005
Suzhou Transcenta Therapeutics Co., Ltd.
Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm
09/23
09/23
TST003 / Transcenta
NCT05731271: A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Active, not recruiting
1/2
111
US
TST003
Suzhou Transcenta Therapeutics Co., Ltd.
Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
05/25
08/25
TST010 / Transcenta
No trials found
TST004 / Transcenta
No trials found
TST008 / Transcenta
No trials found

Download Options